^
    1d
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) (clinicaltrials.gov)
    P3, N=90, Recruiting, Sinocelltech Ltd.
    New P3 trial
    |
    bortezomib • cyclophosphamide
    2d
    Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors. (PubMed, Sci Adv)
    To demonstrate the usefulness of the method for immunotherapy applications, we investigated the interaction of primary multiple myeloma cells with the therapeutic monoclonal antibodies daratumumab and isatuximab and a polyclonal anti-CD38 antibody. Our approach might lay the foundation for improved personalized diagnostics and treatment with therapeutic antibodies.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule)
    |
    Darzalex (daratumumab) • Sarclisa (isatuximab-irfc)
    3d
    GMMG-HD7: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Mar 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
    7d
    A multicenter prospective randomized controlled study of quadruplet regimen in newly diagnosed transplant-ineligible high-risk multiple myeloma patients (ChiCTR2600116772)
    P4, N=117, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    7d
    A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with chronic immune thrombocytopenia (ChiCTR2500115452)
    P1/2, N=75, Completed, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences; CASI Pharmaceuticals (China) Co., Ltd.
    New P1/2 trial
    8d
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P3, N=292, Recruiting, Sinocelltech Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • dexamethasone
    8d
    Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2025
    Trial completion • Trial completion date
    |
    lenalidomide • Darzalex (daratumumab)
    11d
    TAK-079-1006: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy (clinicaltrials.gov)
    P1, N=17, Completed, Takeda | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    mezagitamab (TAK-079)
    14d
    Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. (PubMed, Nephrol Dial Transplant)
    We furthermore discuss genetically engineered CD38 knock-out multitarget natural killer cells, expressing anti-B cell maturation antigen (BCMA) CAR, IL-15RF and hnCD16, administered in combination with daratumumab (anti-CD38) in this context...Likewise, we hypothesize the use of bi-specific T cell engagers such as CD19 blinatumomab or BCMA teclistamab for the treatment of AMR...In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.
    Journal
    |
    IL6 (Interleukin 6) • CD40LG (CD40 ligand)
    |
    Blincyto (blinatumomab) • Darzalex (daratumumab) • Tecvayli (teclistamab-cqyv)
    14d
    Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=122, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Rituxan (rituximab) • Darzalex (daratumumab)
    17d
    TRANSPIRE: A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation (clinicaltrials.gov)
    P2, N=81, Recruiting, Biogen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    felzartamab (MOR202)
    17d
    ATTAIN: Daratumumab and Belatacept for Desensitization (clinicaltrials.gov)
    P1/2, N=19, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Darzalex (daratumumab)